Please assess the completion status of the following clinical trial:

Trial Title: Clinical Management of Neuropathic Pain With Ramelteon

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject will be between ages 18 to 65 years.~2. Subject has not been on ramelteon for at least one month.~3. Subject agrees to make no change in his/her current pain medications during the entire study period (5 weeks). This requirement will ensure that valid comparisons of primary and secondary measures can be made before and after the study.~4. Subject has a VAS pain score of 5 or above at the beginning of the study.~5. Subject has had a neuropathic pain condition as listed above for at least three months. This requirement is to avoid clinical uncertainty from an unstable pain condition and to minimize the study variation.~6. Female subjects of childbearing potential must have a negative urine pregnancy test at the initial visit.~Exclusion Criteria:~1. Subject has moderate to severe liver impairment.~2. Subject has Liver Function Tests (LFT's) \>1.5X normal.~3. Subject has a history of renal impairment.~4. Subject has moderate or severe cardiac or pulmonary disease including a base line oxygen saturation of less than 95% on room air or any requirement for supplemental oxygen.~5. Subject has a history of glaucoma.~6. Subject has obstructive sleep apnea.~7. Subject is taking medications for sleep disorders including insomnia.~8. Subject has a major psychiatric disorder (major depression requiring a recent hospitalization within three months prior to the study; bipolar disorder; schizophrenia; psychotic disorders; substance abuse).~9. Subject has a history of dementia or delirium.~10. Subject has a history of falls.~11. Subject is pregnant or lactating.~12. Subject is using an illicit drug detected by a screening test.~13. Subject is currently taking Fluvoxamine.~14. Subject has been taking Ketoconazole in the past two weeks.~15. Subject has known hypersensitivity to ramelteon.~16. Subject has pending litigation related to his/her neuropathic pain condition.~17. Subject has Concurrent participation in other research drug trials or other study participation within 30 days of enrollment in this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Ramelteon first, placebo second (Type: ACTIVE_COMPARATOR): In a crossover design, a subject will be first assigned to the ramelteon arm and then switched over to the placebo arm. As this is a double-blind study, neither the subject nor the study staff will know which intervention the subject is randomly assigned. The ramelteon dose is 8mg once a night.The ramelteon and placebo will be blinded by the central pharmacy.~The subject is randomly assigned to first receive either ramelteon or placebo. The first intervention will be 14 days long. There is a 7 day washout period, and then the subject is assigned to the opposite intervention. The second intervention will be 14 days long.
- Placebo first, ramelteon second (Type: PLACEBO_COMPARATOR): In a crossover design, a subject will be first assigned to the placebo arm and then switched over to the ramelteon arm. As this is a double-blind study, neither the subject nor the study staff will know which intervention the subject is randomly assigned. The ramelteon dose is 8mg once a night. The ramelteon and placebo will be blinded by the central pharmacy.~The subject is randomly assigned to first receive either ramelteon or placebo. The first intervention will be 14 days long. There is a 7 day washout period, and then the subject is assigned to the opposite intervention. The second intervention will be 14 days long.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues